Chronic kindney disease
Conditions
Brief summary
Changes in indicators of arterial stiffness: pulse wave velocity and pulse pressure
Detailed description
Peripheral and central blood pressure., Biomarcadores del metabolismo mineral (fosfato sérico, calcio y magnesio, FGF23, vitamina D y PTH), 24-hour urinary excretion of phosphate, calcium, sodium, and potassium, Biomarkers of kidney damage: albumin/creatinine ratio, serum creatinine, eGFR, Endothelial function, Serum potassium concentration
Interventions
DRUGRLY5016 Placebo for Oral Suspension was developed for clinical trials and is intended to be administered orally
DRUGsuspended in water
DRUGapple juice or cranberry juice. The patients will be treated with either Placebo or with active drug product
DRUGRLY5016 for Oral Suspension. The Placebo was formulated using microcrystalline cellulose and xanthan gum to produce a powder blend that is packaged into 80 mm × 130 mm individual packets. For Placebo composition please refer to section 3.2.P.1 of IMPD
Sponsors
Fundacion Para La Investigacion Biomedica De Cordoba
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in indicators of arterial stiffness: pulse wave velocity and pulse pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| Peripheral and central blood pressure., Biomarcadores del metabolismo mineral (fosfato sérico, calcio y magnesio, FGF23, vitamina D y PTH), 24-hour urinary excretion of phosphate, calcium, sodium, and potassium, Biomarkers of kidney damage: albumin/creatinine ratio, serum creatinine, eGFR, Endothelial function, Serum potassium concentration | — |
Countries
Spain
Outcome results
None listed